Form 8-K - Current report:
SEC Accession No. 0001347178-20-000027
Filing Date
2020-10-28
Accepted
2020-10-28 16:05:56
Documents
16
Period of Report
2020-10-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vnda-20201028.htm   iXBRL 8-K 45776
2 EX-99.1 vnda8-k102820exhibit991.htm EX-99.1 117228
8 vandaq32019earningsca_imaga.jpg GRAPHIC 49643
  Complete submission text file 0001347178-20-000027.txt   392458

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vnda-20201028.xsd EX-101.SCH 2472
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT vnda-20201028_cal.xml EX-101.CAL 746
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vnda-20201028_def.xml EX-101.DEF 1683
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vnda-20201028_lab.xml EX-101.LAB 24993
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vnda-20201028_pre.xml EX-101.PRE 13226
9 EXTRACTED XBRL INSTANCE DOCUMENT vnda-20201028_htm.xml XML 11216
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

EIN.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 201268673
SIC: 2834 Pharmaceutical Preparations